This site is intended for Healthcare Professionals outside the US

Myelofibrosis is a progressive, relentless, debilitating disease1

Splenomegaly and myelofibrosis symptoms present a significant disease burden2

  • MF is a serious haematologic malignancy with a median survival range of only 2 to 4 years in intermediate-2 and high-risk patients3
  • Worsening, debilitating disease-related symptoms compromise QoL2,4
  • More than 80% of MF patients experience splenomegaly5,6

JAK dysregulation underlies MF and its clinical manifestations1,2

JAK Dysregulation underlies Myelofibrosis and its clinical manifestations - JAKAVI

Adapted from: Mesa RA et al. Haematologica. 2014;99(2):292-298. Verstovsek S et al. N Engl J Med. 2010;363(12):1117-1127.1,2

Myelofibrosis is a life-threatening and debilitating haematologic malignancy3

Next: Splenomegaly is a marker of disease progression in MF

JAK=Janus kinase; MF=myelofibrosis; QoL=quality of life.

References:

  1. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.
  2. Mesa RA, Kiladjian J-J, Verstovsek S, et al. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica. 2014;99(2):292-298.
  3. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
  4. Verstovsek S, Almomen AK, Newberry KJ, Aleem A. Development of ruxolitinib as a myelofibrosis therapy. J Appl Hematol. 2013;4(3):89-95.
  5. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-1708.
  6. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol. 1999;17(9):2954-2970.